| Name | Title | Contact Details |
|---|
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
cladribine, fluphenazine decanoate, pentamidine isethionate, fludarabine phosphate, phentolamine, chloramphenicol, api, us api manufacturer, us api supplier, best gmp manufacturer, most reliable source of api
Pharma-Logic Development is a San Rafael, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Novasite Pharmaceutical is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Everett Laboratories Inc is a West Orange, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.